



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Zalifrelimab

Cat. No.:	HY-P99514
CAS No.:	2148321-69-9
Target:	CTLA-4
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling ^[1] .								
In Vitro	Zalifrelimab (AGEN1884; 0.1, 1, 10 or 100 µg/mL) potently enhances antigen-specific T cell responsiveness that could be potentiated in combination with other immunomodulatory antibodies. Zalifrelimab combined effectively with PD-1 blockade to elicit a T cell proliferative response in the periphery ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Zalifrelimab (AGEN1884; 10 mg/kg; i.v.; on days 1 and 29) is well-tolerated in non-human primates and enhances vaccine-mediated antigen-specific immunity ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus macaques (<i>Macaca fascicularis</i>)^[2]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.; on days 1 and 29</td> </tr> <tr> <td>Result:</td> <td>Enhanced antigen-specific immune responses in combination with reporter vaccines in vivo.</td> </tr> </table>	Animal Model:	Cynomolgus macaques (<i>Macaca fascicularis</i>) ^[2]	Dosage:	10 mg/kg	Administration:	i.v.; on days 1 and 29	Result:	Enhanced antigen-specific immune responses in combination with reporter vaccines in vivo.
Animal Model:	Cynomolgus macaques (<i>Macaca fascicularis</i>) ^[2]								
Dosage:	10 mg/kg								
Administration:	i.v.; on days 1 and 29								
Result:	Enhanced antigen-specific immune responses in combination with reporter vaccines in vivo.								

REFERENCES

[1]. David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. *J Clin Oncol*. 2022 Mar 1;40(7):762-771.

[2]. Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. *PLoS One*. 2018 Apr 4;13(4):e0191926.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA